Novel three-antigen TB vaccine to boost protection in adults
Official title: Development of a Novel Trivalent Adjuvanted TB Vaccine
Funded at Beth Israel Deaconess Medical Center · NIH-11451222 · Data updated 2026-11-12
A new vaccine approach for TB in adults aims to improve protection by combining three specific TB antigens with an immune-boosting adjuvant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 3, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $1,296,750 |
| NIH project number | 1R01AI202713-01 |
| Project ID | NIH-11451222 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older who may be eligible for TB vaccine trials in the future.
✕Less likely to help
People with conditions that preclude vaccination or who are not part of the TB vaccine development pathway may not benefit.
What this research studies
This project seeks to develop a next-generation TB vaccine for adults using a trivalent formulation that includes PPE20, EsxG, and PE18 with an adjuvant to enhance immune responses. Researchers will test candidate vaccines in preclinical models and study how the immune system, particularly CD4 T cells, responds to these antigens. The goal is to identify a vaccine strategy that produces stronger and broader protection than BCG, guiding future clinical testing in people who have lived with TB risk. If successful, the work could shorten the path to a more protective vaccine option for adults at risk of TB.
Why it matters
Potential benefit: If successful, this vaccine could provide better protection against TB for adults, potentially reducing illness and death.
How similar studies have gone: Previous work has shown that targeted antigen combinations can influence protective efficacy, but many top protective antigens are not yet in clinical development.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Barouch, Dan H. — Beth Israel Deaconess Medical Center
- Study coordinator: Barouch, Dan H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.